What's hot
View all perspectives
Bimekizumab (BKZ), a monoclonal antibody that selectively targets both IL-17A and IL-17F, was evaluated in the BE MOBILE 1 (non-radiographic axSpA) and BE MOBILE 2 (radiographic axSpA) trials and found to yield significant clinical benefit – around 60% of patients in both trials achieved an Assessment in SpondyloArthritis international Society (ASAS)40 response rate, with i
For many women, the journey to motherhood brings a sense of anticipation and joy. However, for those with rheumatoid arthritis, this journey presents unique challenges. At ACR Convergence 2024, researchers discussed how advancements in reproductive medicine and RA management are paving the way for improved outcomes.
Dr. John Cush RheumNow
9 months 2 weeks ago
Finding the Right Combination Therapy in RA
Dr. Jonathan Kay interviews Dr. Ernest Choy about abstract 0521, Transcriptome Analysis of Drug Response in a Large Cohort of Immune-Mediated Inflammatory Disease Patients Supports Advanced Combination Therapy in RA, presented at… https://t.co/yPmDIZ6aKI https://t.co/cairKrbDDu
Dr. John Cush RheumNow
9 months 2 weeks ago
RheumNow Day 4 Recap: ACR Convergence 2024 Highlights https://t.co/WvQB7y0bkm
Dr. John Cush RheumNow
9 months 2 weeks ago
RheumNow’s expanded coverage of the #ACR24 annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Dr. John Cush RheumNow
9 months 2 weeks ago
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Jiha Lee JihaRheum
9 months 2 weeks ago
Time the💉
Response to pneumococcal vaccine better when given before starting MTX.
Stay updated on ACR and EULAR vaccination recommendations!
#ACR24 @RheumNow ABST#2676
Mrinalini Dey DrMiniDey
9 months 2 weeks ago
How long before starting MTX should pts receive PCV13 vaccine?
➡️In RA, PCV13 vaccine given 1 month before starting MTX led to significantly higher immunological response at 1 month compared to pts vaccinated on MTX
⏩Vaccinate pts before starting MTX
Ab2676 #ACR24 @RheumNow
Akhil Sood MD AkhilSoodMD
9 months 2 weeks ago
Abstract 2681: #SDOH factors & SLE risk:
- Low income (AOR=2.779).
- By race/ethnicity NHB (AOR=2.429), Hispanic (AOR=1.616).
Behavioral: Psych distress (AOR=2.127), no exercise (AOR=1.677).
Access: Medicaid (AOR=2.540), transport barriers (AOR=20.394).
@RheumNow #ACR24
Antoni Chan MD (Prof) synovialjoints
9 months 2 weeks ago
For daily recaps, content and updates from #ACR24 head to https://t.co/eL0bMhnFiu @RheumNow with input from colleagues in the faculty
@synovialjoints
@bella_mehta
@ericdeinmd
@AkhilSoodMD.
@DrMiniDey
@CaoilfhionnMD
@ebrhuem
@rheumarampa
@Dr_Brian_MD
@AdelaCastro222
@JihaRheum… https://t.co/a3FQjGokhn https://t.co/1g3Fi01HWG
Janet Pope Janetbirdope
9 months 2 weeks ago
#Ianalumab
300 mg sc q monthly
B cell depleted and changes BAFF signalling
👇⬇️IFN
May be promising in #lupus #SLE
+data in primary #Sjogrens
ACR24 @RheumNow @ACRheum
Abst#2425
Needs Phase3
➡️I suspect safer than CAR T and Bispecific T cell engagers but
? ⬇️efficacy
Janet Pope Janetbirdope
9 months 2 weeks ago
ACR24 take homes
➡️#Inflammatory #myositis
#Upadacitinib improved MDA5 ILD
#Baricitinib 4mg/d good in myositis delayed start #RCT
#Tofacitinb ➡️help for skin, calcinosis, rash in case series
➡️RCT ongoing
JAKi is ‘jacked’ in muscles 💪🏿
#ACR24 @RheumNow @ACRheum
1731 0348
Janet Pope Janetbirdope
9 months 2 weeks ago
Biggest absence award at #ACR24 @ACRheum @RheumNow
🥇
Absence of discussion on
👇
#Oral #Surveillance
Except for maybe
Monitoring for mouth ulcers and cancers
issues are not resolved but we are comfortable with ambiguity!
Dr. John Cush RheumNow
9 months 2 weeks ago
Taking CAR-T for a Test Drive
What is CAR-T? How can you get a healthy dose of it at #ACR24? And what does it mean for the future? Read on to find out!
https://t.co/TnNHzWQndp https://t.co/qWgwjiEdLF
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA). Recently, there is new evidence that sex-related differences play a role not only in disease manifestations but also in efficacy and safety of treatments as well as outcomes and prognosis.
Poster Hall